Last reviewed · How we verify
P2Et extract
At a glance
| Generic name | P2Et extract |
|---|---|
| Also known as | P2Et obtained from Caesalpinia spinosa |
| Sponsor | Hospital Universitario San Ignacio |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety Assessment of P2Et Extract in Healthy Voluntary Subjects in Colombia (PHASE1)
- Safety and Efficacy Evaluation of the P2Et Extract in Patients With Breast Cancer (PHASE2)
- P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P2Et extract CI brief — competitive landscape report
- P2Et extract updates RSS · CI watch RSS
- Hospital Universitario San Ignacio portfolio CI